BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 25225064)

  • 1. Concurrent alterations in TERT, KDM6A, and the BRCA pathway in bladder cancer.
    Nickerson ML; Dancik GM; Im KM; Edwards MG; Turan S; Brown J; Ruiz-Rodriguez C; Owens C; Costello JC; Guo G; Tsang SX; Li Y; Zhou Q; Cai Z; Moore LE; Lucia MS; Dean M; Theodorescu D
    Clin Cancer Res; 2014 Sep; 20(18):4935-48. PubMed ID: 25225064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Next-generation sequencing of urine specimens: A novel platform for genomic analysis in patients with non-muscle-invasive urothelial carcinoma treated with bacille Calmette-Guérin.
    Scott SN; Ostrovnaya I; Lin CM; Bouvier N; Bochner BH; Iyer G; Solit D; Berger MF; Lin O
    Cancer Cytopathol; 2017 Jun; 125(6):416-426. PubMed ID: 28339163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma.
    Gossage L; Murtaza M; Slatter AF; Lichtenstein CP; Warren A; Haynes B; Marass F; Roberts I; Shanahan SJ; Claas A; Dunham A; May AP; Rosenfeld N; Forshew T; Eisen T
    Genes Chromosomes Cancer; 2014 Jan; 53(1):38-51. PubMed ID: 24166983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic Subtypes of Non-invasive Bladder Cancer with Distinct Metabolic Profile and Female Gender Bias in KDM6A Mutation Frequency.
    Hurst CD; Alder O; Platt FM; Droop A; Stead LF; Burns JE; Burghel GJ; Jain S; Klimczak LJ; Lindsay H; Roulson JA; Taylor CF; Thygesen H; Cameron AJ; Ridley AJ; Mott HR; Gordenin DA; Knowles MA
    Cancer Cell; 2017 Nov; 32(5):701-715.e7. PubMed ID: 29136510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC.
    Ibragimova I; Maradeo ME; Dulaimi E; Cairns P
    Epigenetics; 2013 May; 8(5):486-93. PubMed ID: 23644518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.
    Pietzak EJ; Bagrodia A; Cha EK; Drill EN; Iyer G; Isharwal S; Ostrovnaya I; Baez P; Li Q; Berger MF; Zehir A; Schultz N; Rosenberg JE; Bajorin DF; Dalbagni G; Al-Ahmadie H; Solit DB; Bochner BH
    Eur Urol; 2017 Dec; 72(6):952-959. PubMed ID: 28583311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic.
    Williams EA; Santagata S; Wakimoto H; Shankar GM; Barker FG; Sharaf R; Reddy A; Spear P; Alexander BM; Ross JS; Brastianos PK; Cahill DP; Ramkissoon SH; Juratli TA
    Acta Neuropathol Commun; 2020 Oct; 8(1):171. PubMed ID: 33087175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2.
    Ler LD; Ghosh S; Chai X; Thike AA; Heng HL; Siew EY; Dey S; Koh LK; Lim JQ; Lim WK; Myint SS; Loh JL; Ong P; Sam XX; Huang D; Lim T; Tan PH; Nagarajan S; Cheng CW; Ho H; Ng LG; Yuen J; Lin PH; Chuang CK; Chang YH; Weng WH; Rozen SG; Tan P; Creasy CL; Pang ST; McCabe MT; Poon SL; Teh BT
    Sci Transl Med; 2017 Feb; 9(378):. PubMed ID: 28228601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations.
    Palsgrove DN; Taheri D; Springer SU; Cowan M; Guner G; Mendoza Rodriguez MA; Rodriguez Pena MDC; Wang Y; Kinde I; Ricardo BFP; Cunha I; Fujita K; Ertoy D; Kinzler KW; Bivalacqua TJ; Papadopoulos N; Vogelstein B; Netto GJ
    Hum Pathol; 2019 Mar; 85():1-9. PubMed ID: 30447301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular identification of telomerase reverse transcriptase (TERT) promotor mutations in primary and recurrent tumors of invasive and noninvasive urothelial bladder cancer.
    Roggisch J; Ecke T; Koch S
    Urol Oncol; 2020 Mar; 38(3):77.e17-77.e25. PubMed ID: 31521529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small-cell Carcinomas of the Urinary Bladder and Prostate: TERT Promoter Mutation Status Differentiates Sites of Malignancy and Provides Evidence of Common Clonality Between Small-cell Carcinoma of the Urinary Bladder and Urothelial Carcinoma.
    Priemer DS; Wang M; Zhang S; Lopez-Beltran A; Kouba E; Montironi R; Davidson DD; MacLennan GT; Wang L; Osunkoya AO; Deng Y; Emerson RE; Cheng L
    Eur Urol Focus; 2018 Dec; 4(6):880-888. PubMed ID: 28753872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular alterations associated with metastases of solid pseudopapillary neoplasms of the pancreas.
    Amato E; Mafficini A; Hirabayashi K; Lawlor RT; Fassan M; Vicentini C; Barbi S; Delfino P; Sikora K; Rusev B; Simbolo M; Esposito I; Antonello D; Pea A; Sereni E; Ballotta M; Maggino L; Marchegiani G; Ohike N; Wood LD; Salvia R; Klöppel G; Zamboni G; Scarpa A; Corbo V
    J Pathol; 2019 Jan; 247(1):123-134. PubMed ID: 30306561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism.
    Rachakonda PS; Hosen I; de Verdier PJ; Fallah M; Heidenreich B; Ryk C; Wiklund NP; Steineck G; Schadendorf D; Hemminki K; Kumar R
    Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17426-31. PubMed ID: 24101484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implication of
    Matar M; Prince G; Hamati I; Baalbaky M; Fares J; Aoude M; Matar C; Kourie HR
    Pharmacogenomics; 2023 Jun; 24(9):509-522. PubMed ID: 37458596
    [No Abstract]   [Full Text] [Related]  

  • 15. Significance of KDM6A mutation in bladder cancer immune escape.
    Chen X; Lin X; Pang G; Deng J; Xie Q; Zhang Z
    BMC Cancer; 2021 May; 21(1):635. PubMed ID: 34051747
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Kobatake K; Ikeda KI; Nakata Y; Yamasaki N; Ueda T; Kanai A; Sentani K; Sera Y; Hayashi T; Koizumi M; Miyakawa Y; Inaba T; Sotomaru Y; Kaminuma O; Ichinohe T; Honda ZI; Yasui W; Horie S; Black PC; Matsubara A; Honda H
    Clin Cancer Res; 2020 Apr; 26(8):2065-2079. PubMed ID: 32047002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer.
    Wang K; Liu T; Liu C; Meng Y; Yuan X; Liu L; Ge N; Liu J; Wang C; Ren H; Yan K; Hu S; Xu Z; Fan Y; Xu D
    Oncologist; 2015 Mar; 20(3):263-9. PubMed ID: 25657201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. X chromosome protects against bladder cancer in females via a
    Kaneko S; Li X
    Sci Adv; 2018 Jun; 4(6):eaar5598. PubMed ID: 29928692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological and clinical perspectives of TERT promoter mutation detection on bladder cancer diagnosis and management.
    Cheng L; Zhang S; Wang M; Lopez-Beltran A
    Hum Pathol; 2023 Mar; 133():56-75. PubMed ID: 35700749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatic alteration and depleted nuclear expression of BAP1 in human esophageal squamous cell carcinoma.
    Mori T; Sumii M; Fujishima F; Ueno K; Emi M; Nagasaki M; Ishioka C; Chiba N
    Cancer Sci; 2015 Sep; 106(9):1118-29. PubMed ID: 26081045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.